{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-001822","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.335347+00:00","generated_at":"2026-05-24T02:28:08.617443+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Calidi Biotherapeutics reports Q4 net loss of $4.1M; files IND for CLD-201 solid tumor trial","bullets":["Q4 2024 net loss $4.1M ($0.27/share) vs $8.2M loss ($0.23/share) in Q4 2023.","Full year 2024 net loss $23.8M ($2.97/share) vs $29.2M ($17.33/share) in 2023.","Cash and restricted cash $9.8M as of Dec 31, 2024, up from $2.1M as of Dec 31, 2023.","IND filed in March 2025 for CLD-201 Phase 1 trial in solid tumors (breast, head&neck, sarcoma).","CLD-101 Phase 1 trial for high-grade glioma started recruiting at Northwestern; 14th patient treated at City of Hope."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-001822","json":"https://secwatch.observer/filing/0001641172-25-001822.json","markdown":"https://secwatch.observer/filing/0001641172-25-001822.md","text":"https://secwatch.observer/filing/0001641172-25-001822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225001822/0001641172-25-001822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225001822/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:28:08.617443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}